Future studies should prioritize mechanistic validation—such as in vitro knockdown/overexpression experiments in B-ALL cell lines and patient-derived xenograft models—to determine whether CADPS loss directly contributes to therapeutic resistance or disease progression. This evidence concerns the gene CADPS and acute lymphoblastic leukemia.